

## Supporting Information

### Selective modification of tryptophan in polypeptides via C-N coupling with azoles using *in-situ* generated iodine-based oxidants in aqueous media



Shunsuke Watanabe, Yuki Wada, Masaki Kawano, Shuhei Higashibayashi, Takeshi Sugai, and Kengo Hanaya\*

#### Table of Contents

Supporting data .....	3
Additional experimental data for tryptophan modification of polypeptides via C-N coupling with benzotriazole <b>2</b> .....	14
Experimental information .....	38
1. General information .....	38
2. Methods for HPLC analyses for analytical scale and preparative scale .....	39
3. Methods for LC-MS and LC-MS/MS .....	39
4. Experimental procedures .....	40
4.1. C-N coupling of Ac-Trp-NHEt ( <b>1</b> ) and benzotriazole ( <b>2</b> ) in the presence of Ac-Tyr-NHEt ( <b>3</b> ) .....	40
4.2. Determination of the degree of racemization of <b>4</b> during the C-N coupling of Ac-Trp-NHEt ( <b>1</b> ) and benzotriazole ( <b>2</b> ) .....	40
4.3. C-N coupling of Ac-Trp-NHEt ( <b>1</b> ) and benzotriazole ( <b>2</b> ) in the presence of Ac-Tyr-NHEt ( <b>3</b> ) with I <sub>2</sub> or NIS under buffered condition .....	41
4.4. C-N coupling of Ac-Trp-OCH <sub>3</sub> ( <b>5</b> ) and azoles with KI and KIO <sub>3</sub> .....	41
4.5. Structural confirmation of <b>7</b> by <sup>1</sup> H NMR .....	41
4.6. X-ray crystallographic analysis of <i>N</i> -acetyl-2-( <i>1H</i> -1,2,3-triazol-1-yl)-L-tryptophan methyl ester ( <b>7</b> ) .....	41
4.7. General procedure for modification of peptides through C-N coupling with benzotriazole ( <b>2</b> ) .....	42


4.8. Modification of LHRH through C–N coupling with azoles.....	43
4.9. Analytical-scale preparation of stapled peptide <b>29</b> via the intramolecular C–N coupling for analytical scale.....	43
4.10. Scale-up preparation of stapled peptide <b>29</b> for NMR experiments .....	44
4.11. CD spectroscopy of peptides.....	44
<b>5. Method for quantification of modified peptides.....</b>	<b>44</b>
<b>6. Preparation of amino acid derivatives as authentic samples for RP-HPLC analyses.</b>	<b>45</b>
<b>7. Preparation ofazole derivatives.....</b>	<b>49</b>
<b>References .....</b>	<b>86</b>

## Supporting data


		<sup>13</sup> C NMR (δ, ppm)	
		<b>4</b> (126 MHz, CDCl <sub>3</sub> )	<b>I</b> (100 MHz, CDCl <sub>3</sub> )
 <b>4</b>		 compound <b>I</b>	
		<sup>13</sup> C NMR (δ, ppm)	
<b>4</b> (500 MHz, CDCl <sub>3</sub> )	<b>I</b> (400 MHz, CDCl <sub>3</sub> )	<b>4</b> (126 MHz, CDCl <sub>3</sub> )	<b>I</b> (100 MHz, CDCl <sub>3</sub> )
7.22-7.25 (m, 1H)	7.22-7.26 (m, 1H)	107.4	106.8
7.31-7.34 (m, 1H)	7.34 (td, <i>J</i> = 8.0, 1.2 Hz, 1H)	110.3	110.3
7.41 (d, <i>J</i> = 8.2 Hz, 1H),	7.42-7.47 (m, 2H)	111.8	111.3
7.47 (ddd, <i>J</i> = 2.5, 5.4, 8.1 Hz, 1H)	7.48-7.51 (m, 1H)	120.2	119.7
7.57-7.58 (m, 2H),	7.54-7.58 (m, 1H)	120.6	120.3
7.79 (d, <i>J</i> = 8.0 Hz, 1H),	7.68 (d, <i>J</i> = 8.0 Hz, 1H)	121.3	120.4
8.11 (d, <i>J</i> = 8.4 Hz, 1H),	8.14 (d, <i>J</i> = 8.0 Hz, 1H)	124.5	123.9
9.06 (s, 1H).	8.49 (s, 1H)	125.4	124.6
		127.0	125.8
		127.1	127.9
		129.5	128.7
		133.8	133.9
		134.4	134.3
		145.6	145.4

**Fig. S1** Structural confirmation of **4** by comparison of <sup>1</sup>H and <sup>13</sup>C NMR spectra of aromatic region (<sup>1</sup>H NMR: δ 7.00-10.00, <sup>13</sup>C NMR: δ 100.0-150.0) between **4** and 2-(benzotriazol-1-yl)-3-methylindole (**I**).<sup>1</sup>


**Table S1** Optimization of reaction conditions for C–N coupling of tryptophan **1** with benzotriazole (**2**)





entry	oxidant	[oxidant] (mM)	[KI] (mM)	[CH <sub>3</sub> SO <sub>3</sub> H] (mM)	[ <b>2</b> ] (mM)	time (min)	temp.	conversion (%) <sup>a</sup>		yield (%) <sup>b</sup>		
								<b>1</b>	<b>3</b>	<b>4</b>	<b>S1</b>	<b>S2</b>
1	I <sub>2</sub>	1	0	0	25	30	r.t.	78	33	15	20	6
2	NIS	1	0	0	25	30	r.t.	88	>95	21	7	>95
3	HIO <sub>3</sub>	1	0	0	25	30	r.t.	8	<5	<5	<5	<5
4	HIO <sub>3</sub>	1	0.5	0	25	30	r.t.	36	9	9	7	<5
5	KIO <sub>3</sub>	1	0.5	1	25	30	r.t.	38	10	9	7	<5
6	KIO <sub>3</sub>	1	0.5	10	25	30	r.t.	>95	31	21	21	9
7	KIO <sub>3</sub>	1	0.5	20	25	10	r.t.	>95	8	16	8	<5
8	KIO <sub>3</sub>	1	0.5	20	50	10	r.t.	>95	13	25	8	<5
9	KIO <sub>3</sub>	1	0.5	20	100	10	r.t.	>95	15	38	8	<5
10	KIO <sub>3</sub>	1	0.5	20	100	30	0 °C	85	<5	47	<5	<5
11	KIO <sub>3</sub>	0.5	0.25	20	100	60	0 °C	86	5	49	<5	<5
12	KIO <sub>3</sub>	1	0.25	20	100	60	0 °C	>95	<5	61	<5	<5
13	I <sub>2</sub>	1	0	20	100	60	0 °C	73	6	47	9	<5
14	NIS	1	0	20	100	60	0 °C	>95	13	40	<5	<5
15	KIO <sub>3</sub>	1	0	20	100	60	0 °C	53	<5	20	<5	<5




**Fig. S2** RP-HPLC chromatograms of the authentic samples of (a) **1**, (b) **3**, (c) **4**, (d) **S1**, and (e) **S2** in the presence of **2** and the reaction mixtures of (f) entry 1, (g) entry 2, and (h) entry 12 in Table S1.



**Fig. S3** HPLC chromatograms and peak tables for (a) racemic **1**, (b) racemic **4**, (c) L-**1**, and (d) the crude product of the C–N coupling of **1** and **2**. Peaks No.1–4 in (d) were judged not to be the D-**4** according to the UV spectral data collected with the PDA detector.




**Fig. S4** (a) C–N coupling of tryptophan **1** and **2** with I<sub>2</sub> or NIS as an oxidant at various pH in the presence of tyrosine **3**. (b) pH dependency of the conversions of **1** and **3** and the yields of **4**, **S1**, and **S2**.




**Fig. S5** RP-HPLC chromatograms of the authentic samples of (a) **5**, (b) **6**, (c) **7**, (d) **8**, and (e) **9** and the reaction mixtures with (f) benzotriazole, (g) triazole, (h) pyrazole, and (i) benzimidazole.









**Fig. S6** Confirmation of the C–N coupling of 1,2,3-triazole at the N1 nitrogen by  $^1\text{H}$  NMR in  $\text{CDCl}_3$ . Numbers on each signal correspond to numbers on the structures. (a) The authentic sample of **7** and (b) the crude product of the C–N coupling of **5** and 1,2,3-triazole.




**Fig. S7** The crystal structure of *N*-acetyl-2-(1*H*-1,2,3-triazol-1-yl)-*L*-tryptophan methyl ester (**7**). The positive peaks (green wire mesh) in the difference electron density map ( $0.2 \text{ e}\text{\AA}^{-3}$  level) suggested the presence of the hydrogen atoms, which indicated the attachment of the triazole ring at the N1 position. The dotted line indicated the hydrogen bonding.



**Fig. S8** Equilibrium of iodine species in an aqueous condition.




**Fig. S9** Possible reaction mechanisms of the C–N coupling reaction and the side reactions.




**Fig. S10** Fragmentation of LHRH (14) under the reaction conditions in the absence of 2. ESI-MS spectrum of the reaction mixture.

**Additional experimental data for tryptophan modification of polypeptides via C–N coupling with benzotriazole 2**


**Table S2** Exploration of additives for suppression of undesirable methionine oxidation




entry	[KI] (mM)	[KIO <sub>3</sub> ] (mM)	additives	[additives] (mM)	temp.	time (min)	area ( <b>19</b> ) / area ( <b>10+19<sub>ox</sub></b> )
1	0.5	2	–	0	r.t.	30	0.17
2	0.5	2	–	0	0 °C	30	3.55
3	0.5	2	thiourea	0.25	0 °C	30	3.22
4	0.5	2	thiourea	2	0 °C	30	1.75
5	0.5	2	HCO <sub>2</sub> H	5	0 °C	30	3.82
6	0.5	2	HCO <sub>2</sub> H	20	0 °C	30	4.35
7	0.25	1	HCO <sub>2</sub> H	20	0 °C	60	5.85



**Fig. S11** RP-HPLC chromatograms for Table S2.









**Fig. S12** Tryptophan modification of polypeptides via C–N coupling with **2**. RP-HPLC chromatograms of the parent peptides (top) and the reaction mixtures (bottom): (a) neuromedin B (**10**) (H-GNLWATGHFM-NH<sub>2</sub>), (b) bombesin (**11**) (pEQRLGNQWAVHLM-NH<sub>2</sub>), (c)  $\alpha$ -MSH (**12**), (Ac-SYSMEHFRWGKPV-NH<sub>2</sub>), (d) kisspeptin-10 (**13**) (H-YNWNSFGLRF-NH<sub>2</sub>), (e) LHRH (**14**) (pEHWSYGLRPG-NH<sub>2</sub>), (f) somatostatin (**15**) [H-AGCKNFFWKTFTSC-OH (C<sup>3</sup>-C<sup>13</sup>)], (g) synthetic peptide **16** (H-WRVYI-OH), (h) synthetic peptide **17** (H-YRVYI-OH), and (i) endokinin D (**18**) (H-GAYQLEHTFQGLL-NH<sub>2</sub>).

(a)

**19** (H-GNLWATGHFM-NH<sub>2</sub>)  
calcd for [M + H]<sup>+</sup>: 1249.5




**19<sub>ox</sub>** (H-GNLWATGHFM-NH<sub>2</sub>)  
calcd for [M + H]<sup>+</sup>: 1265.6




(b)

**20** (pEQRLGNQWAVHLM-NH<sub>2</sub>)  
calcd for [M + H]<sup>+</sup>: 1736.9




**20<sub>ox</sub>** (pEQRLGNQWAVHLM-NH<sub>2</sub>)  
calcd for [M + H]<sup>+</sup>: 1752.9





(c)

**21** (Ac-SYSMEHFRWGKPV-NH<sub>2</sub>)  
calcd for [M + H]<sup>+</sup>: 1781.8




**21<sub>ox</sub>** (Ac-SYSMEHFRWGKPV-NH<sub>2</sub>)  
calcd for [M + H]<sup>+</sup>: 1797.8





**Fig. S13** MALDI-TOF MS spectra of modified peptides **19**—**24** after RP-HPLC purification. An additional [M-28+H]<sup>+</sup> peak derived from N<sub>2</sub> loss from the benzotriazole was observed.<sup>2</sup>

Precursor ion: 869.0 (m/z), Collision energy: -35.0 V





Simulated fragment list

b-N <sub>2</sub>	b		y	y-N <sub>2</sub>		
		pE				
	b2	240.1	Q	y13	1625.8	
	b3	396.2	R	y12	1497.8	
	b4	509.3	L	y11	1341.7	
	b5	566.3	G	y10	1228.6	
	b6	680.3	N	y9	1171.6	
	b7	808.4	Q	y8	1057.5	
b8-N <sub>2</sub>	1083.5	b8	1111.5	W	y7	929.5
b9-N <sub>2</sub>	1154.5	b9	1182.6	A	y6	626.3
b10-N <sub>2</sub>	1253.6	b10	1281.6	V	y5	555.3
b11-N <sub>2</sub>	1310.6	b11	1338.6	G	y4	456.2
b12-N <sub>2</sub>	1447.7	b12	1475.7	H	y3	399.2
b13-N <sub>2</sub>	1560.8	b13	1588.8	L	y2	262.2
			M-NH <sub>2</sub>	y1	149.1	

**Fig. S14** LC-MS/MS analysis data of modified bombesin **20**. Denitrogenated b ions (b-N<sub>2</sub>) and y ions (y-N<sub>2</sub>) were also observed. Detected fragment ions were highlighted in red (b ions) or blue (y ions).

Precursor ion: 891.8 (m/z), Collision energy: -35.0 V





Simulated fragment list

b-N <sub>2</sub>	b		y	y-N <sub>2</sub>
		Ac-S		
	b2	293.1 Y	y12	1652.8 y12-N <sub>2</sub> 1624.8
	b3	380.1 S	y11	1489.7 y11-N <sub>2</sub> 1461.7
	b4	511.2 M	y10	1402.7 y10-N <sub>2</sub> 1374.7
	b5	640.2 E	y9	1271.7 y9-N <sub>2</sub> 1243.6
	b6	777.3 H	y8	<b>1142.6</b> y8-N <sub>2</sub> 1114.6
	b7	924.2 F	y7	1005.6 y7-N <sub>2</sub> 977.5
	b8	1080.5 R	y6	858.5 y6-N <sub>2</sub> 830.5
b9-N <sub>2</sub>	1355.6	b9 1383.6 <b>W</b>	y5	<b>702.4</b> y5-N <sub>2</sub> 674.4
b10-N <sub>2</sub>	1412.6	b10 1440.6 G	y4	<b>399.3</b>
b11-N <sub>2</sub>	1540.7	b11 1568.7 K	y3	342.3
b12-N <sub>2</sub>	1637.7	b12 1665.7 P	y2	<b>214.2</b>
		V-NH <sub>2</sub>	y1	117.1

**Fig. S15** LC-MS/MS analysis data of modified  $\alpha$ -MSH **21**. Denitrogenated b ions (b-N<sub>2</sub>) and y ions (y-N<sub>2</sub>) were also observed. Detected fragment ions were highlighted in red (b ions) or blue (y ions).

Precursor ion: 710.6 (m/z), Collision energy: -35.0 V





Simulated fragment list

b-N <sub>2</sub>		b		y		y-N <sub>2</sub>		
				Y				
		b2	278.1	N	y9	1256.6	y9-N <sub>2</sub>	1228.6
b3-N <sub>2</sub>	553.2	b3	581.2	<b>W</b>	y8	1142.6	y8-N <sub>2</sub>	<b>1114.6</b>
b4-N <sub>2</sub>	667.3	b4	695.3	N	y7	<b>839.5</b>		
b5-N <sub>2</sub>	754.3	b5	782.3	S	y6	<b>725.4</b>		
b6-N <sub>2</sub>	901.4	b6	929.4	F	y5	<b>638.4</b>		
b7-N <sub>2</sub>	958.4	b7	986.4	G	y4	<b>491.3</b>		
b8-N <sub>2</sub>	1071.5	b8	1099.5	L	y3	434.3		
b9-N <sub>2</sub>	1227.6	b9	1255.6	R	y2	321.2		
				F-NH <sub>2</sub>	y1	165.1		

**Fig. S16** LC-MS/MS analysis data of modified kisspeptin-10 **22**. Denitrogenated b ions (b-N<sub>2</sub>) and y ions (y-N<sub>2</sub>) were also observed. Detected fragment ions were highlighted in red (b ions) or blue (y ions).

Precursor ion: 1299.5 (m/z), Collision energy: -35.0 V





Simulated fragment list

b-N <sub>2</sub>	b		y	y-N <sub>2</sub>				
		pE						
	b2	249.1	H	y9				
				1188.6				
				y9-N <sub>2</sub>				
				1160.5				
b3-N <sub>2</sub>	524.2	b3	552.2	W	y8	1051.5	y8-N <sub>2</sub>	1023.5
b4-N <sub>2</sub>	611.2	b4	639.2	S	y7	748.4		
b5-N <sub>2</sub>	774.3	b5	802.3	Y	y6	661.4		
b6-N <sub>2</sub>	831.3	b6	859.3	G	y5	498.3		
b7-N <sub>2</sub>	944.4	b7	972.4	L	y4	441.3		
b8-N <sub>2</sub>	1100.5	b8	1128.5	R	y3	328.2		
b9-N <sub>2</sub>	1197.6	b9	1225.6	P	y2	172.1		
			G-NH <sub>2</sub>	y1	75.1			

**Fig. S17** LC-MS/MS analysis data of modified LHRH **23**. Denitrogenated b ions (b-N<sub>2</sub>) and y ions (y-N<sub>2</sub>) were also observed. Detected fragment ions were highlighted in red (b ions) or blue (y ions).

Precursor ion: 878.9 (m/z), Collision energy: -35.0 V




Simulated fragment list



b-N <sub>2</sub>	b		y	y-N <sub>2</sub>		
		A				
	b2	<b>129.1</b>	G	y13	1685.7	
	b3	232.1	C	y12	1628.7	
	b4	<b>360.2</b>	K	y11	1525.7	
	b5	<b>474.2</b>	N	y10	1397.6	
	b6	<b>621.3</b>	F	y9	1283.6	
	b7	<b>768.3</b>	F	y8	1136.5	
b8-N <sub>2</sub>	1043.5	b8	<b>1071.5</b>	<b>W</b>	y7	989.4
b9-N <sub>2</sub>	1171.6	b9	1199.6	K	y6	<b>686.3</b>
b10-N <sub>2</sub>	<b>1272.6</b>	b10	1300.6	T	y5	<b>558.2</b>
b11-N <sub>2</sub>	1419.7	b11	1447.7	F	y4	<b>457.2</b>
b12-N <sub>2</sub>	1520.7	b12	1548.7	T	y3	<b>310.1</b>
b13-N <sub>2</sub>	1607.7	b13	1635.8	S	y2	<b>209.1</b>
			C	y1	122.0	

**Fig. S18** LC-MS/MS analysis data of modified somatostatin **24**. Denitrogenated b ions (b-N<sub>2</sub>) and y ions (y-N<sub>2</sub>) were also observed. Detected fragment ions were highlighted in red (b ions) or blue (y ions).






**Fig. S19** Aromatic regions of <sup>1</sup>H NMR spectra of **14** and **23**. The red and green letters indicated the signals of the indole and the benzotriazole, respectively. Numbers on each signal corresponded to numbers on the structures.




**Fig. S20** Aromatic region of  $^{13}\text{C}$  NMR spectra of **14** and **23**. The red and green letters indicated the signals of the indole and the benzotriazole, respectively. Numbers on each signal corresponded to numbers on the structures.

**Table S3**  $^1\text{H}$  NMR assignment for LHRH (**14**) and the modified LHRH **23**. N.D.: not determined.


		LHRH ( <b>14</b> )		<b>23</b>	
		$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$
pE1	NH	7.77	–	7.60-7.57	–
	1	3.97-3.95	55.5	3.96-3.94	55.4
	2	2.17-2.12, 1.76-1.73	25.2	2.14-2.06, 1.66-1.61	24.9
	3	2.10-2.00	29.1	2.05-1.98	N.D.
	4	–	178.0	–	177.4
H2	NH	8.02-8.01	–	8.00 (d, J = 8.2 Hz)	–
	1	4.43-4.38	52.9	4.46-4.42	51.4
	2	2.89-2.86, 2.78-2.75	N.D.	2.95-2.92, 2.82-2.78	26.9
	3	–	N.D.	–	129.0
	4	7.48 (d, J = 0.6 Hz)	134.8	8.89	133.8
	5	N.D.	N.D.	7.19	116.9
W3	NH	8.15 (d, J = 7.3 Hz)	–	8.04 (d, J = 7.6 Hz)	–
	1	4.56-4.53	53.5	4.70-4.66	53.1
	2	3.17-3.14, 2.97-2.95	27.4	3.22-3.19, 2.90-2.86	26.3
	3	–	109.9	–	105.8
	4	–	127.4	–	126.5
	5	7.56 (d, J = 8.0 Hz)	118.2	7.92 (d, J = 8.0 Hz)	120.1
	6	9.2 (dd, J = 8.0, 7.1 Hz)	118.4	7.10 (dd, J = 8.0, 7.3 Hz)	119.7
	7	7.03 (dd, J = 8.1, 7.1 Hz)	120.8	7.25 (dd, J = 8.2, 7.3 Hz)	123.1
	8	7.30 (d, J = 8.1 Hz)	111.2	7.42 (d, J = 8.2 Hz)	111.8
	9	–	136.0	–	134.2
	10	7.11	123.6	–	127.2
	11	–	–	–	133.9
	12	–	–	–	144.8
	13	–	–	8.21 (d, J = 8.4 Hz)	119.6
	14	–	–	7.52 (dd, J = 7.2 Hz)	124.9
	15	–	–	7.60-7.57	129.0
	16	–	–	7.65 (d, J = 8.3 Hz)	110.9
	indole NH	10.81	–	11.98	–
S4	NH	8.41	–	8.09 (d, J = 7.5 Hz)	–
	1	4.31-4.28	55.4	4.22-4.19	54.8
	2	3.59-3.57, 3.50-3.48	61.5	3.56-3.51	61.7
Y5	NH	8.02-8.01	–	7.92 (d, J = 8.0 Hz)	–
	1	4.41-4.38	54.6	4.41-4.38	54.5
	2	2.96-2.93, 2.75-2.72	36.4	2.92-2.90, 2.72-2.68	36.5
	3	–	127.7	–	127.6
	4	7.01 (d, J = 8.5 Hz)	130.1	7.01 (d, J = 8.5 Hz)	130.1
	5	6.61 (d, J = 8.5 Hz)	114.9	6.61 (d, J = 8.5 Hz)	114.9
	6	–	155.8	–	155.8
G6	NH	8.28	–	8.24 (t, J = 5.9 Hz)	–
	1	3.59-3.57	41.9	3.65-3.61, 3.59-3.55	41.8
L7	NH	7.90 (d, J = 8.1 Hz)	–	7.87 (d, J = 8.2 Hz)	–
	1	4.38-4.33	50.7	4.35-4.31	50.7
	2	1.47-1.39	40.9	1.41-1.38	41.1
	3	1.60-1.57	24.1	1.58-1.53	24.1
	4	0.86 (d, J = 6.6 Hz)	23.1, 21.5	0.85 (d, J = 6.5 Hz)	23.1, 21.5
		0.83 (d, J = 6.6 Hz)		0.82 (d, J = 6.5 Hz)	
R8	NH	8.23-8.21	–	8.20-8.18	–
	1	4.56-4.53	50.1	4.46-4.42	50.1
	2	1.72-1.68, 1.60-1.54	27.9	1.71-1.68, 1.58-1.53	28.1
	3	1.54-1.47	24.4	1.53-1.49	24.5
	4	3.02-2.99	40.4	3.12-3.04	40.6
	5	–	157.3	–	156.6
	guanidineNH	8.62	–	7.47-7.45	–
P9	1	4.26-4.23	59.9	4.27-4.25	59.8
	2	2.10-1.98, 1.85-1.82	29.0	2.05-1.98	N.D.
	3	1.97-1.92, 1.85-1.82	24.6	1.94-1.90, 1.83-1.79	24.6
	4	3.56-3.53	46.9	3.70-3.66, 3.56-3.51	47.0
G10	NH	8.24-8.22	–	8.20-8.18	–
	1	3.75-3.66	42.0	3.70-3.66	42.0




**Fig. S21** Tryptophan modification of WRVYI via the C–N coupling with **2**. (a) MALDI-TOF MS spectrum of the crude reaction mixture. (b) RP-HPLC chromatograms of **16** (top) and the reaction mixture (bottom).




**Fig. S22** Tryptophan modification of LHRH (**14**) via the C–N coupling with **25**–**27**. RP-HPLC chromatograms of the crude reaction mixtures with (a) **25**, (b) **26**, and (c) **27**.



**Fig. S23** MALDI-TOF MS spectra of modified peptides with **25**—**27** after RP-HPLC purification. An additional  $[M-28+H]^+$  peak derived from  $N_2$  loss from the benzotriazole was observed.<sup>2</sup>




**Fig. S24** (a) The two-step reaction scheme for stapling of kisspeptin-10 (**13**). (b) Analytical RP-HPLC chromatograms of kisspeptin-10 (**13**) (top) and the reaction mixture of reductive amination of **13** with **28** and  $\text{NaBH}_3\text{CN}$  (bottom). (c) MALDI-TOF MS spectrum of the crude reaction mixture of the reductive amination. (d) RP-HPLC chromatogram and (e) MALDI-TOF MS spectrum of purified TP-**13**.




**Fig. S24** (continued) (f) RP-HPLC chromatograms of the crude reaction mixture of intramolecular C-N coupling after incubation for a given time period. (g) MALDI-TOF MS spectrum of the crude reaction mixture of intramolecular C-N coupling after incubation for 3 h. A peak at  $m/z$  839 was assigned to the peptide fragment which was formed through cleavage at C-terminal side of tryptophan.<sup>3</sup> Peaks at  $m/z$  1427 ( $\Delta M = +16$  amu) and 1443 ( $\Delta M = +32$  amu) were assumed to be oxidized TP-13 ( $m/z$  1411). (h) MALDI-TOF MS spectrum of purified 29.






**Fig. S25** Aromatic region of <sup>1</sup>H NMR spectra of TP-13 and 29. The red arrows indicates the signals of the indole rings. Numbers on each signal correspond to numbers on the structures.




**Fig. S26** Aromatic region of  $^{13}\text{C}$  NMR spectra of TP-13 and 29. The signals of the indole rings in each spectrum were highlighted in red. Numbers on each signal correspond to numbers on the structures.

**Table S4** <sup>1</sup>H NMR assignment for kisspeptin-10 (13), TP-13, stapled peptide 29. N.D.: not determined.

		kisspeptin-10 (13)		TP-13		stapled peptide 29	
		<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C
TP	1			2.83-2.72	45.7	3.03-2.92	45.3
	2			1.91-1.79	25.5	2.08-2.03	24.9
	3			2.65-2.61	22.0	2.96-2.81	22.3
	4			-	130.6	-	145.2
	5			N.D.	125.1	8.32	125.1
Y1	NH		-	8.99, 8.60	-	8.63	-
	1	3.29-3.26	56.7	3.97-3.93	60.8	3.88	62.7
	2	2.84-2.79, 2.41-2.37	N.D.	2.93-2.79	35.8	3.00-2.91	35.7
	3	-	129.0	-	124.0	-	124.8
	4	6.97 (d, J = 8.5 Hz)	130.6	6.95 (d, J = 8.5 Hz)	130.8	7.02 (d, J = 8.2 Hz)	130.9
	5	6.66 (d, J = 8.5 Hz)	115.5	6.62 (d, J = 8.5 Hz)	115.8	6.70 (d, J = 8.2 Hz)	115.9
6	-	156.2	-	157.0	-	157.1	
N2	NH	8.32	-	8.75	-	8.62	-
	1	4.62-4.58	50.3	4.71-4.65	50.2	4.18	51.6
2	2.62-2.58, 2.52-2.48	37.6	2.62-2.57, 2.44-2.38	37.6	2.70-2.67, 2.52-2.46	36.3	
W3	NH	8.11	-	8.176	-	8.00	-
	1	4.48-4.45	54.2	4.52-4.48	54.2	4.44-4.39	54.3
	2	3.17-3.14, 2.98-2.94	27.7	3.15-3.12, 2.98-2.93	28.0	3.05-3.01, 2.97-2.94	26.7
	3	-	110.3	-	110.3	-	103.7
	4	-	127.8	-	127.8	-	127.1
	5	7.54 (d, J = 7.9 Hz)	118.8	7.57 (d, J = 7.7 Hz)	118.8	7.52 (d, J = 7.8 Hz)	120.3
	6	6.94-6.91	118.7	6.97-6.93	118.7	7.09-7.05	120.3
	7	7.03-7.01	121.2	7.04-7.01	121.3	7.17-7.14	123.1
	8	7.28 (d, J = 8.1 Hz)	111.7	7.28 (d, J = 8.0 Hz)	111.7	7.32 (d, J = 8.0 Hz)	111.9
	9	-	136.5	-	136.5	-	133.8
10	7.15 (d, J = 2.0 Hz)	124.2	7.12 (d, J = 2.2 Hz)	124.0	-	N.D.	
indole NH	10.79	-	10.75	-	11.95	-	
N4	NH	8.19-8.16	-	8.26	-	8.12	-
	1	4.54-4.52	49.7	4.71-4.65	50.2	4.60-4.55	50.1
2	2.49-2.45	37.8	2.65-2.57, 2.47-2.38	37.9	2.56-2.52, 2.34-2.31	38.1	
S5	NH	7.99	-	7.93	-	7.94	-
	1	4.19-4.17	56.3	4.22-4.17	56.1	3.96-3.91	56.3
2	3.58-3.56, 3.52-3.49	61.8	-	61.8	3.54-3.50, 3.48-3.43	61.6	
F6	NH	8.19-8.16	-	8.1	-	8.07	-
	1	4.44-4.39	54.2	4.44-4.40	54.0	4.44-4.40	54.0
	2	3.01-2.97, 2.84-2.79	38.0	3.01-2.96, 2.83-2.79	38.0	3.07-3.01, 2.89-2.85	37.1
	3	-	138.4 or 138.2	-	138.3 or 138.1	-	138.3 or 138.1
	4	7.24-7.22	128.6 or 128.5	7.24-7.20	128.6 or 128.5	7.26-7.15	128.6 or 128.5
	5	7.24-7.20	129.6	7.24-7.17	129.6	7.26-7.15	129.6
6	7.17-7.14	126.7	7.19-7.15	126.7	7.26-7.15	126.7	
G7	NH	8.19-8.16	-	8.11	-	8.01	-
	1	3.77-3.74, 3.70-3.66	42.7	3.72-3.70	42.6	3.67	42.6
L8	NH	7.91	-	7.84	-	7.78	-
	1	4.32-4.28	51.6	4.32-4.28	51.5	4.30-4.24	51.5
	2	1.47-1.39	41.0	1.47-1.36	41.2	1.45-1.35	41.1
	3	1.61-1.56	24.5	1.61-1.55	24.5	1.61-1.51	24.5
4	0.87 (d, J = 6.7 Hz)	23.6	0.86 (d, J = 6.6 Hz)	23.6	0.86 (d, J = 6.6 Hz)	23.6	
5	0.82 (d, J = 6.5 Hz)	22.0	0.82 (d, J = 6.5 Hz)	22.0	0.82 (d, J = 6.5 Hz)	22.0	
R9	NH	8.19-8.16	-	8.06	-	7.41	-
	1	4.20-4.16	52.9	4.22-4.17	52.8	4.19	52.8
	2	1.63-1.58	28.9	1.65-1.60, 1.52-1.47	29.3	1.66-1.47	29.4
	3	1.42-1.34	25.2	1.45-1.35	25.4	1.45-1.35	25.4
4	3.01-2.97	40.5	3.07-3.01	40.9	3.07-3.03	40.9	
F10	NH	7.88	-	7.79	-	7.71	-
	1	4.44-4.39	55.1	4.45-4.41	55.1	4.40-4.35	55.2
	2	3.10-3.06, 2.91-2.87	37.3	3.08-3.04, 2.92-2.87	37.4	3.03-2.99, 2.85-2.79	38.1
	3	-	138.4 or 138.2	-	138.3 or 138.1	-	138.3 or 138.1
	4	7.24-7.22	128.6 or 128.5	7.24-7.20	128.5 or 128.6	7.26-7.15	128.5 or 128.6
	5	7.24-7.20	129.6	7.24-7.17	129.6	7.26-7.15	129.6
6	7.17-7.14	126.7	7.19-7.15	126.7	7.26-7.15	126.7	



**Fig. S27** ROESY experiment data. Gray arrows indicated the correlation suggesting C–N bond formation.



**Fig. S28** The results of secondary structure analyses by a BeStSel program. (a) (c) Fitting results for **13** and **29**. (b) (d) The tables of secondary structure contents for **13** and **29**.

## Experimental information

### 1. General information

All chemical reagents and solvents, which were purchased were used without further purification. Neuromedin B (4152-v), bombesin (4086-v), somatostatin (4023-v), luteinizing hormone-releasing hormone (human) (4013-v),  $\alpha$ -melanocyte-stimulating hormone (4057-v), and endokinin D (4412-v) were purchased from peptide institute. Kisspeptin-10 (human) was purchased from peptide institute (4389-v) and Selleck chemicals (E2037). WRVYI and YRVYI were synthesized by Fmoc-based solid-phase peptide synthesis. The molar extinction coefficient at 280 nm of each peptide was computed by Expsy ProtParam tool.

Silica gel column chromatography was performed using Wakosil<sup>®</sup> C-300 (spherical and neutral, 40-64  $\mu$ m, 233-01677, Fujifilm Wako pure chemical Co.), and the Isolera One flash purification system (Biotage). Preparative TLC was performed with PLC silica gel 60 F254, 0.5 mm (Merck). IR spectra were measured on a Jeol FT-IR SPX60 spectrometer. <sup>1</sup>H NMR spectra were measured at 500 MHz on Bruker AVANCE 500 spectrometers or 600 MHz on Bruker AVANCE 600 spectrometers. <sup>13</sup>C NMR spectra were measured at 126 MHz on a Bruker AVANCE 500 spectrometers or 151 MHz on a Bruker AVANCE 600 spectrometers. CDCl<sub>3</sub>, DMSO-*d*<sub>6</sub>, and methanol-*d*<sub>4</sub> were used as a solvent and the residual solvent peaks were used as an internal standard (<sup>1</sup>H NMR: CDCl<sub>3</sub> 7.26 ppm, methanol-*d*<sub>4</sub> 3.31 ppm, DMSO-*d*<sub>6</sub> 2.50 ppm; <sup>13</sup>C NMR: CDCl<sub>3</sub> 77.16 ppm, methanol-*d*<sub>4</sub> 49.00 ppm, DMSO-*d*<sub>6</sub>, 39.52 ppm). High resolution mass spectra (HRMS) were recorded on JEOL JMS-T100LP AccuTOF. Reverse-phase high-performance liquid chromatography (RP-HPLC) was performed with CBM-20A, SPD-10A VP, LC-20AD, and CTO-10AS VP (Shimadzu) using CAPCELL PAK C18 MGII (4.6 mm $\times$ 250 mm, Shiseido), Discovery<sup>®</sup> BIO Wide Pore C18 (4.6 mm $\times$ 250 mm, Sigma), or COSMOSIL 5C18-MS-II (10 x 250 mm, Nacalai tesque). The flow rates were 1.0 mL/min for analytical scale and 4.0 mL/min for preparative scale. In every RP-HPLC analysis, a gradient of 0.1% trifluoroacetic acid (TFA) in H<sub>2</sub>O (mobile phase A) and 0.1% TFA in acetonitrile (mobile phase B) was employed. Compounds were detected by UV detector at 280 nm. Enantiomeric excesses of compounds were analyzed by HPLC using CBM-20A, SPD-20A, SPD-M20A, LC-20AB, CTO-10AS VP (Shimadzu) and CHIRALPAK<sup>®</sup> ID-3 (4.6 mm $\times$ 250 mm, DAICEL) with hexane and 2-propanol as mobile phases. Compounds were detected by UV detector at 254 nm. MALDI-TOF MS analysis was performed on MALDI-8020 (Shimadzu).  $\alpha$ -Cyano-4-hydroxycinnamic acid (CHCA) (20 mg/mL solution in 50:50:0.1 H<sub>2</sub>O/MeCN/TFA) or 3,5-dimethoxy-4-hydroxycinnamic acid (SA) (20 mg/mL solution in 50:50:0.1 H<sub>2</sub>O/MeCN/TFA) was used as a matrix in MALDI-TOF MS analysis. LC-MS and LC-MS/MS analyses were conducted on CBM-20A, SPD-20A, LC-20AD, CTO-20A, SIL-20AC HT, and LCMS-8050 (Shimadzu) with CAPCELL PAK C18 MGII (4.6 mm $\times$ 250 mm, Shiseido). A gradient of 0.1% formic acid (FA) in H<sub>2</sub>O (mobile phase A) and 0.1% FA in acetonitrile (mobile

phase B) was employed. UV-vis spectra were recorded on V-770 UV-VIS-NIR spectrometer (JASCO). CD spectra were recorded on J-1100 (JASCO).

## 2. Methods for HPLC analyses for analytical scale and preparative scale

Method A:

gradient: 10% B for 3 min, 10–30% B over 1 min, 30% B for 5 min, 30–95% B over 10 min, 95% B for 5 min. column: Discovery<sup>®</sup> BIO Wide Pore C18 (4.6 mm×250 mm, Sigma), flow rate: 1.0 mL/min temperature: 30 °C.

Method B:

gradient: 20% B for 3 min, 20–95% B over 16 min, 95% B for 5 min, column: CAPCELL PAK C18 MGII (4.6 mm×250 mm, Shiseido), flow rate: 1.0 mL/min, temperature: 30 °C.

Method C (for endokinin D):

gradient: 20% B for 10 min, 20–95% B over 10 min, 95% B for 5 min, column: CAPCELL PAK C18 MGII (4.6 mm×250 mm, Shiseido), flow rate: 1.0 mL/min, temperature: 30 °C.

Method D (for LHRH modified with **25**):

gradient: 20% B for 8 min, 20–95% B over 16 min, 95% B for 5 min, column: CAPCELL PAK C18 MGII (4.6 mm×250 mm, Shiseido), flow rate: 1.0 mL/min, temperature: 30 °C.

Method E (for peptide stapling):

gradient: 20% B for 3 min, 20–95% B over 16 min, 95% B for 5 min, column: CAPCELL PAK C18 MGII (4.6 mm×250 mm, Shiseido), flow rate: 1.0 mL/min, temperature: 30 °C.

Method F (for purification of TP-**13** and stapled peptide **23**):

gradient: 20% B for 8 min, 20–95% B over 16 min, 95% B for 5 min, column: COSMOSIL 5C18-MS-II (10 x 250 mm), flow rate: 4.0 mL/min, temperature: r.t..

Method G (for the analysis of enantiomeric excesses of **1** and **4**)

Isocratic elution: 25% 2-propanol, column: CHIRALPAK ID-3 (4.6 mm×250 mm, DAICEL), flow rate: 1.0 mL/min, temperature: 25 °C.

## 3. Methods for LC-MS and LC-MS/MS

Method A:

gradient: 20% B for 3 min, 20–95% B over 16 min, 95% B over 5 min, column: CAPCELL

PAK C18 MGII (4.6 mm×250 mm, Shiseido), flow rate: 1.0 mL/min.

Method B:

gradient: 20% B for 10 min, 20–95% B over 25 min, 95% B for 10 min, column: CAPCELL PAK C18 MGII (4.6 mm×250 mm, Shiseido), flow rate: 0.2 mL/min.

#### 4. Experimental procedures

##### 4.1. C–N coupling of Ac-Trp-NHEt (1) and benzotriazole (2) in the presence of Ac-Tyr-NHEt (3)

To a mixture of Ac-Trp-NHEt (1) [2  $\mu$ L, 5 mM in DMSO (final conc.: 0.25 mM)], Ac-Tyr-NHEt (3) [2  $\mu$ L, 5 mM in DMSO (final conc.: 0.25 mM)], benzotriazole (2) [4  $\mu$ L, 250, 500 or 1000 mM in DMSO (final conc.: 25, 50 or 100 mM)], MeSO<sub>3</sub>H [4  $\mu$ L, 10 or 100 mM in H<sub>2</sub>O (final conc.: 1 or 10 mM), or 8  $\mu$ L, 100 mM in H<sub>2</sub>O (final conc. 20 mM)], and KI [2  $\mu$ L, 5 mM in H<sub>2</sub>O (final conc.: 0.25 mM), or 4  $\mu$ L, 5 mM in H<sub>2</sub>O (final conc.: 0.5 mM)], DMSO and H<sub>2</sub>O (required volume to adjust the total volume of the reaction mixture and the DMSO/H<sub>2</sub>O ratio to 40  $\mu$ L and 25/75), was added I<sub>2</sub>, NIS [2  $\mu$ L, 20 mM in DMSO (final conc.: 1 mM)] or KIO<sub>3</sub> [4  $\mu$ L, 5 mM or 10 mM in H<sub>2</sub>O (final conc.: 0.5 or 1 mM)]. The mixture was incubated at given temperature for a given time period. The mixture was quenched with Na<sub>2</sub>SO<sub>3</sub> (10  $\mu$ L, 500 mM in H<sub>2</sub>O) and diluted with H<sub>2</sub>O (30  $\mu$ L). The resulting solution (40  $\mu$ L) was analyzed by RP-HPLC using method A. Retention times: **1**: 11.9 min; **3**: 7.3 min; **4**: 15.4 min; **S1**: 11.7 min; **S2**: 14.0 min.

Yields of **4**, **S1** and **S2** were determined by comparison of peak area with that of separately prepared authentic samples (see section 6). Conversion of the substrates were defined as (100% – residual rate).

##### 4.2. Determination of the degree of racemization of 4 during the C–N coupling of Ac-Trp-NHEt (1) and benzotriazole (2)

To a mixture of Ac-Trp-NHEt (1) [4  $\mu$ L, 5 mM in DMSO (final conc.: 0.25 mM)], benzotriazole (2) [8  $\mu$ L, 1000 mM in DMSO (final conc.: 100 mM)], MeSO<sub>3</sub>H [16  $\mu$ L, 100 mM in H<sub>2</sub>O (final conc. 20 mM)], and KI [4  $\mu$ L, 5 mM in H<sub>2</sub>O (final conc.: 0.25 mM)], DMSO (8  $\mu$ L) and H<sub>2</sub>O (32  $\mu$ L), was added KIO<sub>3</sub> [8  $\mu$ L, 10 mM in H<sub>2</sub>O (final conc.: 1 mM)]. The mixture was incubated in an ice bath for 1 h. The mixture was quenched with Na<sub>2</sub>SO<sub>3</sub> (20  $\mu$ L, 500 mM in H<sub>2</sub>O) and diluted with H<sub>2</sub>O (160  $\mu$ L). The organic materials were extracted with AcOEt (200  $\mu$ L and 100  $\mu$ L×2). The combined organic layers were evaporated and dissolved in 2-propanol (50  $\mu$ L). The resulting solution (20  $\mu$ L) was analyzed by HPLC using method G.

Retention times: L-1: 16.2 min, D-1: 7.9 min, L-4: 34.1 min, D-4: 13.6 min.

The enantiomeric excesses of L-1 and **4** were calculated by comparison of the peak areas of L-



and D-isomers.

#### **4.3. C–N coupling of Ac-Trp-NHEt (1) and benzotriazole (2) in the presence of Ac-Tyr-NHEt (3) with I<sub>2</sub> or NIS under buffered condition**

To an ice-cold mixture of Ac-Trp-NHEt (1) [2  $\mu$ L, 5 mM in DMSO (final conc.: 0.25 mM)], Ac-Tyr-NHEt (3) [2  $\mu$ L, 5 mM in DMSO (final conc.: 0.25 mM)], benzotriazole (2) [4  $\mu$ L, 1 M in DMSO (final conc.: 100 mM)], H<sub>2</sub>O (10  $\mu$ L) and citrate buffer (20  $\mu$ L, 100 mM in H<sub>2</sub>O, a given pH) was added I<sub>2</sub> or NIS [2  $\mu$ L, 20 mM in DMSO (final conc.: 1 mM)]. The reaction mixture was incubated in an ice bath for 1 h. Work-up and RP-HPLC analysis were performed in the same manner as section 4.1.

#### **4.4. C–N coupling of Ac-Trp-OCH<sub>3</sub> (5) and azoles with KI and KIO<sub>3</sub>**

To an ice-cold mixture of Ac-Trp-OMe (5) [2  $\mu$ L, 5 mM in DMSO (final conc.: 0.25 mM)], azoles [4  $\mu$ L, 1 M in DMSO or H<sub>2</sub>O (final conc.: 100 mM)], MeSO<sub>3</sub>H [8  $\mu$ L, 100 mM in H<sub>2</sub>O (final conc.: 20 mM)], KI [2  $\mu$ L, 5 mM in H<sub>2</sub>O (final conc.: 0.25 mM), or 4  $\mu$ L, 5 mM in H<sub>2</sub>O (final conc.: 0.5 mM)], DMSO and H<sub>2</sub>O (required volume to adjust the total volume of the reaction mixture and the DMSO/H<sub>2</sub>O ratio to 40  $\mu$ L and 25/75), was added KIO<sub>3</sub> [4  $\mu$ L, 10 or 20 mM in H<sub>2</sub>O (final conc.: 1 or 2 mM)]. The reaction mixture was incubated in an ice bath for 1 h and was quenched with Na<sub>2</sub>SO<sub>3</sub> (10  $\mu$ L, 500 mM in H<sub>2</sub>O) and diluted with H<sub>2</sub>O (30  $\mu$ L). The resulting solution (40  $\mu$ L) was analyzed by RP-HPLC using method B.

Retention times: **5**: 14.1 min; **6**: 16.1 min; **7**: 13.3 min; **8**: 15.4 min; **9**: 13.5 min.

Yields of **6**, **7**, and **8** were determined by comparison of the peak areas with those of separately prepared authentic samples (see section 6). Conversion of the substrates were defined as (100% – residual rate).

#### **4.5. Structural confirmation of 7 by <sup>1</sup>H NMR**

To an ice-cold mixture of Ac-Trp-OMe (5) (3.0 mg, 0.012 mmol), 1,2,3-triazole (232  $\mu$ L, 4.00 mmol), MeSO<sub>3</sub>H (52  $\mu$ L, 0.80 mmol), and KI (3.5 mg, 0.021 mmol) in DMSO (2 mL) and H<sub>2</sub>O (38 mL), was added KIO<sub>3</sub> (17 mg, 0.079 mmol). The reaction mixture was incubated in an ice bath for 1 h and was quenched with Na<sub>2</sub>SO<sub>3</sub> (630 mg). The organic materials were extracted with CHCl<sub>3</sub> (10 mL $\times$ 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The resulting residue (4 mg) was analyzed by <sup>1</sup>H NMR in CDCl<sub>3</sub>.

#### **4.6. X-ray crystallographic analysis of *N*-acetyl-2-(1*H*-1,2,3-triazol-1-yl)-L-tryptophan methyl ester (7)**

The analysis of **7** was performed on a on a Rigaku Synergy-R/DWTI APEX II instrument with a

Hypix-6000HE detector (Cu-K $\alpha$ ,  $\lambda = 1.514184 \text{ \AA}$ , T = 123.15K). The structures were solved by Dual space methods (SHELXT-2018) and refined by full-matrix least squares calculations on  $F^2$  (SHELXL-2018) using the SHELX-TL program package. All non-hydrogen atoms were refined with anisotropic displacement parameters. All hydrogen atoms were created with ideal geometry and refined using a riding model.

Crystallographic data have been deposited with Cambridge Crystallographic Data Centre: Deposition number CCDC-2298364. Copies of the data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html> (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge, CB2 1EZ, UK; Fax: +44 1223 336033; e-mail: [deposit@ccdc.cam.ac.uk](mailto:deposit@ccdc.cam.ac.uk)). The single crystal of **7** was prepared by a vapor diffusion method. *N*-Acetyl-2-(*1H*-1,2,3-triazol-1-yl)-L-tryptophan methyl ester (**7**) was dissolved in AcOEt. The solution in a micro vial was put into a vial filled with hexane and was stayed overnight. Crystal data of **7**: C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O<sub>3</sub>, colorless, 0.72 × 0.52 × 0.15 mm<sup>3</sup>, monoclinic, space group *P*2<sub>1</sub> (No. 4),  $a = 8.78319(6)$ ,  $b = 10.61767(7)$ ,  $c = 9.51916(6) \text{ \AA}$ ,  $\alpha = 90^\circ$ ,  $\beta = 114.9580(8)^\circ$ ,  $\gamma = 90^\circ$ ,  $V = 804.830(11) \text{ \AA}^3$ ,  $\rho_{\text{calcd}} = 1.351 \text{ g/cm}^3$ ,  $Z = 2$ , 3159 unique reflections ( $R_{\text{int}} = 0.0278$ ,  $R_{\text{sigma}} = 0.0139$ ) out of 3170 with  $I > 2\sigma(I)$  reflections measured,  $R_1 = 0.0231$ , and  $wR_2 = 0.0640$  [ $I > 2\sigma(I)$ ],  $R_1 = 0.0240$ , and  $wR_2 = 0.0674$  for all data, GOF = 1.051, and flack parameter = 0.001(6). When the structure was solved as the N2-coupling adduct, the R factor increased from 2.66 % to 3.89 %, supporting the structure assignment. Furthermore, the crystal structure of *N*-acetyl-2-(*1H*-1,2,3-triazol-1-yl)-L-tryptophan methyl ester with difference electron density map (0.2 e $\text{\AA}^{-3}$  level) confirmed the synthesis of N1 coupling adduct (Fig.S7).

#### **4.7. General procedure for modification of peptides through C–N coupling with benzotriazole (2)**

To an ice-cold mixture of peptides [2  $\mu\text{L}$ , 2.5 mM in H<sub>2</sub>O (final conc.: 0.25 mM)], benzotriazole [2  $\mu\text{L}$ , 1 M in DMSO (final conc.: 100 mM)], MeSO<sub>3</sub>H [4  $\mu\text{L}$ , 100 mM in H<sub>2</sub>O (final conc.: 20 mM)], HCO<sub>2</sub>H [2  $\mu\text{L}$ , 200 mM in H<sub>2</sub>O (final conc.: 20 mM)], KI [1  $\mu\text{L}$ , 5 mM in H<sub>2</sub>O (final conc.: 0.25 mM)], or 2  $\mu\text{L}$ , 5 mM in H<sub>2</sub>O (final conc.: 0.5 mM)], and H<sub>2</sub>O (6 or 7  $\mu\text{L}$ , required volume to adjust the total volume of the reaction mixture to 20  $\mu\text{L}$ ), was added KIO<sub>3</sub> [2  $\mu\text{L}$ , 10 or 20 mM in H<sub>2</sub>O (final conc.: 1 or 2 mM)]. The reaction mixture was incubated in an ice bath for 1 h, quenched with Na<sub>2</sub>SO<sub>3</sub> (5  $\mu\text{L}$ , 500 mM in H<sub>2</sub>O), and diluted with H<sub>2</sub>O (3  $\mu\text{L}$ ). Only for somatostatin, sodium ascorbate (8  $\mu\text{L}$ , 100 mM in H<sub>2</sub>O) was used instead of Na<sub>2</sub>SO<sub>3</sub> to prevent from reduction of the disulfide bond. To the mixture was added 1-naphthol (2  $\mu\text{L}$ , 10 mM in DMSO). The resulting solution (20  $\mu\text{L}$ ) was analyzed by RP-HPLC using method B except for endokinin D (method C). After separation by RP-HPLC, each product was identified by MALDI-TOF MS and LC-MS/MS analyses. For LC-MS/MS analysis of modified somatostatin, reaction mixture was quenched with

Na<sub>2</sub>SO<sub>3</sub> (5 μL, 500 mM in H<sub>2</sub>O) and was incubated overnight at room temperature before the analysis (method A).

#### 4.8. Modification of LHRH through C–N coupling with azoles

benzotriazole **25**:

To a cold mixture of LHRH [2 μL, 2.5 mM in H<sub>2</sub>O (final conc.: 0.25 mM)], **25** [2 μL, 1 M in DMSO (final conc.: 100 mM)], MeSO<sub>3</sub>H [4 μL, 100 mM in H<sub>2</sub>O (final conc.: 20 mM)], HCO<sub>2</sub>H [2 μL, 200 mM in H<sub>2</sub>O (final conc.: 20 mM)], KI [2 μL, 5 mM in H<sub>2</sub>O (final conc.: 0.5 mM)], DMSO (3 μL) and H<sub>2</sub>O (3 μL), was added KIO<sub>3</sub> (2 μL, 20 mM in H<sub>2</sub>O). The mixture was incubated at 10 °C in a cryostat (UC reactor, Techno Sigma) for 1 h. Work-up and RP-HPLC and MALDI-TOF MS analysis were performed in a similar manner to section 4.7. using RP-HPLC method D instead of method B.

1,2,3-triazole derivatives **26** and **27**:

To an ice-cold mixture of LHRH [2 μL, 2.5 mM in H<sub>2</sub>O (final conc.: 0.25 mM)], triazoles [8 μL, 250 mM in H<sub>2</sub>O (final conc.: 100 mM)], MeSO<sub>3</sub>H [4 μL, 100 mM in H<sub>2</sub>O (final conc.: 20 mM)], HCO<sub>2</sub>H [2 μL, 200 mM in H<sub>2</sub>O (final conc.: 20 mM)] and KI [2 μL, 5 mM in H<sub>2</sub>O (final conc.: 0.5 mM)], was added KIO<sub>3</sub> (2 μL, 20 mM in H<sub>2</sub>O). The mixture was incubated in an ice bath for 2 h. Work-up and RP-HPLC and MALDI-TOF MS analyses were performed in the same manner as section 4.7.

#### 4.9. Analytical-scale preparation of stapled peptide **29** via the intramolecular C–N coupling for analytical scale

Kisspeptin-10 (**13**) (200 μL, 2.3 mM in H<sub>2</sub>O) was incubated with **28** (100 μL, 50 mM in DMSO) and NaBH<sub>3</sub>CN (100 μL, 125 mM in 20 mM citrate buffer at pH 6.0) in citrate buffer (2100 μL, 20 mM, pH 6.0) for 16 h at rt. The reaction was quenched with TFA (100 μL). The resulting solution was purified by preparative RP-HPLC (Method F). The fraction at 10.4 min was collected and lyophilized to obtain TP–**13** as a colorless powder. The powder was dissolved in H<sub>2</sub>O (100 μL) and analyzed by analytical RP-HPLC and MALDI-TOF MS. The concentration of TP–**13** was estimated to be 0.78 mM based on UV absorbance at 280 nm. The yield of this step was 34%.

To a cold mixture of TP–**13** (200 μL, 0.78 mM in H<sub>2</sub>O), MeSO<sub>3</sub>H (400 μL, 100 mM in H<sub>2</sub>O), HCO<sub>2</sub>H (200 μL, 200 mM in H<sub>2</sub>O), KI (200 μL, 5 mM in H<sub>2</sub>O), and H<sub>2</sub>O (800 μL), was added KIO<sub>3</sub> (200 μL, 20 mM in H<sub>2</sub>O). The mixture was incubated in an ice bath for 3 h. The reaction was quenched with sodium ascorbate (200 μL, 100 mM in H<sub>2</sub>O). The resulting solution was purified by preparative RP-HPLC (Method F). The fraction at 13.4 min was collected and lyophilized to obtain **29** as a colorless powder. The powder was dissolved in a 1:1 mixture of H<sub>2</sub>O and DMSO (200 μL) and

analyzed by analytical RP-HPLC and MALDI-TOF MS. The concentration of **29** was estimated to be 0.20 mM based on UV absorbance at 280 nm. The yield of this step was 26%.

#### 4.10. Scale-up preparation of stapled peptide **29** for NMR experiments

Kisspeptin-10 (**13**) (5.2 mg) was incubated with **28** (0.8 mL, 50 mM in DMSO) and NaBH<sub>3</sub>CN (0.8 mL, 125 mM in 20 mM citrate buffer at pH 6.0) in citrate buffer (18.4 mL, 20 mM, pH 6.0) for 16 h at rt. The reaction was quenched with TFA (0.8 mL). The resulting solution was purified by preparative RP-HPLC (Method F). The fraction at 10.4 min was collected and lyophilized to obtain TP-**13** as a colorless powder (5.0 mg). The powder was dissolved in DMSO-d<sub>6</sub> (0.7 mL) and analyzed by NMR experiments.

To a cold mixture of a solution of TP-**13** in DMSO (0.7 mL), MeSO<sub>3</sub>H (3.2 mL, 100 mM in H<sub>2</sub>O), HCO<sub>2</sub>H (1.6 mL, 200 mM in H<sub>2</sub>O), KI (1.6 mL, 5 mM in H<sub>2</sub>O), and H<sub>2</sub>O (6.4 mL), was added KIO<sub>3</sub> (1.6 mL, 20 mM in H<sub>2</sub>O). The mixture was incubated in an ice bath for 3 h. The reaction was quenched with sodium ascorbate (1.6 mL, 100 mM in H<sub>2</sub>O). The resulting solution was purified by preparative RP-HPLC (Method F). The fraction at 13.4 min was collected and lyophilized to obtain **23** as a colorless powder (2.4 mg). The powder was dissolved in DMSO-d<sub>6</sub> (0.7 mL) and analyzed by NMR experiments.

#### 4.11. CD spectroscopy of peptides

Kisspeptin-10 (**13**) (15 μL, 2.3 mM in H<sub>2</sub>O) was dissolved in trifluoroethanol (TFE) (285 μL). A solution of **29** in DMSO-d<sub>6</sub> (50 μL, 1.2 mM) was evaporated, and the resulting solids were dissolved in H<sub>2</sub>O (15 μL) and TFE (285 μL). CD spectra of **13** and **29** were recorded at room temperature using 0.1 cm cuvette.

### 5. Method for quantification of modified peptides

Yields of modified peptides were estimated by using peak areas on RP-HPLC chromatograms and molar extinction coefficients of modified peptides. A molar extinction coefficient of an original peptide (sub.) at 280 nm ( $\epsilon_{280}$ ) can be calculated as eq. 1.<sup>4</sup>

$$\epsilon_{280}(\text{sub.}) = 5500 \times (\text{number of Trp}) + 1490 \times (\text{number of Tyr}) + 125 \times (\text{number of disulfide bond})$$

(eq. 1)

Considering molar extinction coefficients of Ac-Trp-OMe (**5**), Ac-2-(benzotriazol-1-yl)-Trp-OMe (**6**), and Ac-2-(triazol-1-yl)-Trp-OMe (**7**) at 280 nm (Table S5), molar extinction coefficients of modified Trp residues in peptides were calculated to be 10010 for a benzotriazole adduct and 8855 for a triazole adduct, respectively. Thus, molar extinction coefficients of

peptides modified with benzotriazole and triazole can be described as eq. 2 and eq. 3.

For a benzotriazole-modified peptide

$$\epsilon_{280}(\text{benzotriazole}) = 10010 \times (\text{Trp}) + 1490 \times (\text{Tyr}) + 125 \times (\text{disulfide bond}) \text{ (eq. 2),}$$

and for a triazole-modified peptide

$$\epsilon_{280}(\text{triazole}) = 8855 \times (\text{Trp}) + 1490 \times (\text{Tyr}) + 125 \times (\text{disulfide bond}) \text{ (eq. 3)}$$

**Table S5** Molar extinction coefficients of **5**, **6**, and **7** at 280 nm

compound	$\epsilon_{280}$ ( $\text{M}^{-1}\text{cm}^{-1}$ )	$\epsilon_{280}(\mathbf{6} \text{ or } \mathbf{7}) / \epsilon_{280}(\mathbf{5})$
<b>5</b>	$5.82 \times 10^3$	-
<b>6</b>	$1.06 \times 10^4$	1.82
<b>7</b>	$9.36 \times 10^3$	1.61

When the Trp modification proceeds quantitatively, the peak area ( $S_{\text{max}}$ ) of the modified peptide can be calculated by using the initial peak area of the original peptide ( $S_0$ ).

$$S_{\text{max}} = \epsilon_{280}(\text{benzotriazole or triazole}) / \epsilon_{280}(\text{sub.}) \times S_0$$

The yield of the modified peptide was calculated from the observed peak area ( $S$ ) on RP-HPLC chromatograms of a reaction mixture.

$$\text{yields of the modified peptide} = S / S_{\text{max}} \times 100$$

Error of the amount of injection was corrected using 1-naphthol as an internal standard.

## 6. Preparation of amino acid derivatives as authentic samples for RP-HPLC analyses

### *N*-Acetyl-L-tryptophan ethylamide (**1**)

Ac-Trp-OEt (841 mg, 3.06 mmol) was dissolved in 70% aqueous ethylamine solution (6 mL). The mixture was stirred for 4 d at room temperature. The reaction mixture was diluted with water (40 mL). The organic materials were extracted with EtOAc (40 mL $\times$ 3). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> solution (40 mL) and brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was washed with water and dried in *vacuo* to afford **1** (640 mg, 76% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  0.94 (dd,  $J = 7.2, 7.2$  Hz, 3H), 1.78 (s, 3H), 2.87 (dd,  $J = 8.6, 14.5$  Hz, 1H), 3.01-3.07 (m, 3H), 4.44 (ddd,  $J = 5.7, 8.4, 8.4$  Hz, 1H), 6.95-6.98 (m, 1H), 7.03-7.06 (m, 1H), 7.10 (d,  $J = 2.1$  Hz, 1H), 7.31 (d,  $J = 8.1$  Hz, 1H), 7.58 (d,  $J = 7.9$  Hz, 1H), 7.91 (dd,  $J = 5.4, 5.5$  Hz, 1H), 7.99 (d,  $J = 8.3$  Hz, 1H), 10.77 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  14.6, 22.6, 28.0, 33.4, 53.4, 110.3, 111.2, 118.1, 118.5, 120.8, 123.4, 127.3, 136.0, 168.9, 171.2. IR (neat, cm<sup>-1</sup>): 3402, 3294, 3102, 2974, 1631, 1539, 1454, 1374, 1287, 1247, 1151, 1092, 1011, 946,

892, 813, 739, 716, 650, 602, 553, 506. HRMS (ESI): calcd for C<sub>15</sub>H<sub>19</sub>N<sub>3</sub>NaO<sub>2</sub> [M+Na]<sup>+</sup> 296.1375, found 296.1372.

#### ***N*-Acetyl-L-tyrosine ethylamide (2)**

*N*-Acetyl tyrosine ethyl ester monohydrate (137 mg, 0.509 mmol) was dissolved in 70% aqueous ethylamine solution (1 mL). The mixture was stirred for 4 d at room temperature. The reaction mixture was acidified with aqueous hydrochloric acid solution (4 M, 10 mL) and saturated with NaCl. The organic materials were extracted with EtOAc (20 mL×2 and 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was washed with diethyl ether and dried in air to afford **2** (93 mg, 73% yield) as colorless solids. <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>): δ 0.92 (dd, *J* = 7.2, 7.2 Hz, 3H), 1.76 (s, 3H), 2.60 (dd, *J* = 9.1, 13.7 Hz, 1H), 2.79 (dd, *J* = 5.5, 13.7 Hz, 1H), 2.99-3.07 (m, 2H), 4.31 (ddd, *J* = 5.5, 8.7, 8.9 Hz, 1H), 6.62 (d, *J* = 8.5 Hz, 1H), 6.99 (d, *J* = 8.5 Hz, 1H), 7.88 (dd, *J* = 5.1, 5.3 Hz, 1H), 7.99 (d, *J* = 8.4 Hz, 1H), 9.14 (d, *J* = 1.1 Hz, 1H). These values were in good agreement with those reported in the literature.<sup>5</sup>

#### ***N*-Acetyl-2-(1H-benzo[d][1,2,3]triazol-1-yl)-L-tryptophan ethylamide (4)**

To a mixture of Ac-Trp-NHEt (**1**) (55 mg, 0.20 mmol) and benzotriazole (60 mg, 0.50 mmol) in MeOH (800 μL) was added *N*-iodosuccinimide (90 mg, 0.40 mmol). The mixture was stirred in an ice bath for 1 h. The reaction was quenched by addition of saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (2 mL) and diluted with water (5 mL). The organic materials were extracted with EtOAc (30 mL and 20 mL). The combined organic layers were washed with 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> solution (10 mL) and brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with Isolera One flash purification system (hexane/EtOAc, 75–100%) to afford **4** (39 mg, 49% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 0.95 (dd, *J* = 7.3, 7.3 Hz, 3H), 1.90 (s, 3H), 3.04-3.12 (m, 3H), 3.17 (dd, *J* = 5.4, 14.8 Hz, 1H), 4.58-4.62 (m, 1H), 6.27 (dd, *J* = 5.3, 5.4 Hz, 1H), 7.18 (d, *J* = 6.6 Hz, 1H), 7.22-7.25 (m, 1H), 7.31-7.34 (m, 1H), 7.41 (d, *J* = 8.2 Hz, 1H), 7.47 (ddd, *J* = 2.5, 5.4, 8.1 Hz, 1H), 7.57-7.58 (m, 2H), 7.79 (d, *J* = 8.0 Hz, 1H), 8.11 (d, *J* = 8.4 Hz, 1H), 9.06 (s, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 14.6, 23.1, 26.0, 34.5, 53.6, 107.4, 110.3, 111.8, 120.2, 120.6, 121.3, 124.5, 125.4, 127.0, 127.1, 129.5, 133.8, 134.4, 145.6, 170.9, 171.2. IR (neat, cm<sup>-1</sup>): 3199, 1739, 1658, 1630, 1548, 1530, 1501, 1469, 1440, 1371, 1342, 1280, 1211, 1048, 1008, 742. HRMS (ESI): calcd for C<sub>21</sub>H<sub>22</sub>N<sub>6</sub>NaO<sub>2</sub> [M+Na]<sup>+</sup> 413.1701, found 413.1701.

#### ***N*-Acetyl-3-iodo-L-tyrosine ethylamide (S1)**

To a solution of Ac-Tyr-NHEt (**3**) (44 mg, 0.20 mmol) and *p*-toluenesulfonic acid monohydrate (37 mg, 0.19 mmol) in MeCN (4 mL), was added *N*-iodosuccinimide (45 mg 0.10 mmol). The mixture was stirred at room temperature for 3 h. To the reaction mixture was added Na<sub>2</sub>SO<sub>3</sub> (38 mg) and concentrated in *vacuo*. The resulting residue was purified with Isolera One flash purification system (EtOAc/ acetone, 0–50%) to afford **S1** (48 mg, 64% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 0.96 (dd, *J* = 7.2, 7.2 Hz, 3H), 1.76 (s, 3H), 2.57 (dd, *J* = 9.2, 13.6 Hz, 1H), 2.77 (dd, *J* = 5.4, 13.6 Hz, 1H), 2.97-3.10 (m, 2H), 4.31 (ddd, *J* = 5.4, 8.7, 8.9 Hz, 1H), 6.75 (d, *J* = 8.2 Hz, 1H), 7.02 (dd, *J* = 2.1, 8.2 Hz, 1H), 7.51 (d, *J* = 2.0 Hz, 1H), 7.93 (dd, *J* = 5.5, 5.6 Hz, 1H), 8.05 (d, *J* = 8.5 Hz, 1H), 10.07 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>): δ 14.6, 22.5, 33.3, 36.6, 54.3, 84.1, 114.5, 130.3, 130.6, 139.1, 155.0, 168.9, 170.7. IR (neat, cm<sup>-1</sup>): 3248, 3068, 2976, 1643, 1536, 1502, 1415, 1367, 1274, 1225, 1146, 1037, 960, 892, 824, 787, 741, 708, 663, 649, 609, 582, 533. HRMS (ESI): calcd for C<sub>13</sub>H<sub>17</sub>IN<sub>2</sub>NaO<sub>3</sub> [M+Na]<sup>+</sup> 399.0182, found 399.0175.

#### ***N*-Acetyl-3,5-diiodo-L-tyrosine ethylamide (S2)**

To a solution of Ac-Tyr-NHEt (**3**) (45 mg, 0.20 mmol) and Na<sub>2</sub>HPO<sub>4</sub>·12H<sub>2</sub>O (210 mg, 0.609 mmol) in MeOH (1 mL) and H<sub>2</sub>O (1 mL) was added I<sub>2</sub> (126 mg 0.512 mmol). The mixture was stirred overnight at room temperature. The reaction was quenched by addition of saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (8 mL) and acidified with 4 M aqueous HCl solution (2 mL) to pH ~4. The organic materials were extracted with EtOAc (40 mL×2). The combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with flush silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 19:1 to 9:1) to afford **S2** (66 mg, 65% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 0.97 (dd, *J* = 7.2, 7.2 Hz, 3H), 1.77 (s, 3H), 2.56 (dd, *J* = 9.3, 13.6 Hz, 1H), 2.76 (dd, *J* = 5.3, 13.6 Hz, 1H), 2.98-3.10 (m, 2H), 4.31 (ddd, *J* = 5.3, 8.8, 9.0 Hz, 1H), 7.59 (s, 2H), 7.97 (dd, *J* = 5.5, 5.5 Hz, 1H), 7.88 (dd, *J* = 5.1, 5.3 Hz, 1H), 8.05 (d, *J* = 8.6 Hz, 1H), 9.34 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>): δ 14.7, 22.4, 33.3, 36.0, 54.0, 84.8, 134.2, 139.6, 153.6, 168.9, 170.4. IR (neat, cm<sup>-1</sup>): 3440, 3266, 3062, 2929, 1644, 1532, 1454, 1401, 1371, 1309, 1275, 1257, 1233, 1185, 1146, 1037, 950, 903, 869, 789, 727, 706, 692, 596. HRMS (ESI): calcd for C<sub>13</sub>H<sub>16</sub>I<sub>2</sub>N<sub>2</sub>NaO<sub>3</sub> [M+Na]<sup>+</sup> 524.9148, found 524.9143.

#### ***N*-Acetyl-L-tryptophan methyl ester (5)**

To a mixture of L-tryptophan methyl ester hydrochloride (2.53 g, 9.93 mmol) in THF (50 mL), were added Ac<sub>2</sub>O (1.1 mL, 12 mmol) and triethylamine (2.8 mL, 20 mmol) in an ice bath. The mixture was stirred overnight at room temperature. The reaction mixture was diluted with H<sub>2</sub>O (50 mL). The organic materials were extracted with EtOAc (50 mL×2). The combined organic

layers were washed with 2 M aqueous HCl solution (40 mL), 2 M aqueous NaHCO<sub>3</sub> solution (40 mL) and brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was washed with diethyl ether to afford **5** (2.07 g, 80% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.96 (s, 3H), 3.28-3.37 (m, 2H), 3.70 (s, 3H), 4.96 (ddd, *J* = 5.3, 5.3, 7.9 Hz, 1H), 5.97 (d, *J* = 7.3 Hz, 1H), 6.98 (d, *J* = 2.4 Hz, 1H), 7.11-7.14 (m, 1H), 7.18-7.22 (m, 1H), 7.36 (d, *J* = 8.1 Hz, 1H), 7.53 (d, *J* = 7.9 Hz, 1H), 8.10 (s, 1H). These values were in good agreement with those reported in the literature.<sup>6</sup>

#### ***N*-Acetyl-2-(1H-benzo[d][1,2,3]triazol-1-yl)-L-tryptophan methyl ester (6)**

To a mixture of Ac-Trp-OMe (**5**) (52 mg, 0.20 mmol), I<sub>2</sub> (12 mg, 0.047 mmol) and benzotriazole (60 mg, 0.50 mmol) in a test tube were added MeOH (400 μL) and H<sub>2</sub>O (400 μL). The mixture was stirred for 5 min at room temperature. Then, 70% aqueous TBHP solution (56 μL, 0.40 mmol) was added to the mixture and the mixture was stirred for 24 h at 40 °C in ChemiStation™ (EYELA). The reaction was quenched by addition of saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (2 mL) and diluted with H<sub>2</sub>O (5 mL). The organic materials were extracted with EtOAc (30 mL and 20 mL). The combined organic layers were washed with brine (15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with Isolera One flash purification system (hexane/EtOAc, 50–100%) to afford **6** (58 mg, 74% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.86 (s, 3H), 3.22 (dd, *J* = 6.9, 14.8 Hz, 1H), 3.32 (dd, *J* = 4.9, 14.8 Hz, 1H), 3.51 (s, 3H), 4.80 (ddd, *J* = 5.0, 6.9, 6.9 Hz, 1H), 6.62 (d, *J* = 7.2 Hz, 1H), 7.26-7.30 (m, 1H), 7.36-7.39 (m, 1H), 7.45 (d, *J* = 7.1 Hz, 1H), 7.49-7.54 (m, 2H), 7.60-7.63 (m, 1H), 7.74 (d, *J* = 7.9 Hz, 1H), 8.19 (d, *J* = 8.4 Hz, 1H), 8.47 (s, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 23.0, 26.1, 52.6, 52.7, 106.6, 110.1, 111.8, 119.9, 120.6, 121.3, 124.6, 125.3, 127.1, 127.2, 129.4, 133.8, 134.4, 145.6, 170.3, 172.0. IR (neat, cm<sup>-1</sup>): 3199, 1739, 1658, 1530, 1501, 1469, 1440, 1371, 1342, 1280, 1211, 1048, 1008, 742, 649, 635, 625. HRMS (ESI): calcd for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>NaO<sub>3</sub> [M+Na]<sup>+</sup> 400.1386, found 400.1382.

#### ***N*-Acetyl-2-(1H-1,2,3-triazol-1-yl)-L-tryptophan methyl ester (7)**

To a mixture of Ac-Trp-OMe (**1**) (52 mg, 0.20 mmol), I<sub>2</sub> (12 mg, 0.047 mmol) and 1,2,3-triazole (30 μL, 0.52 mmol) in a test tube were added MeOH (400 μL) and H<sub>2</sub>O (400 μL). The mixture was stirred for 5 min at room temperature. Then, 70% aqueous TBHP solution (56 μL, 0.40 mmol) was added to the mixture and the mixture was stirred for 24 h at 40 °C in ChemiStation™ (EYELA). The reaction was quenched by addition of saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (2 mL) and diluted with H<sub>2</sub>O (5 mL). The organic materials were extracted with EtOAc (30 mL and 20 mL). The combined organic layers were washed with brine (15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with Isolera




One flash purification system (hexane/ EtOAc, 50–100%) to afford **7** (55 mg, 84% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.89 (s, 3H), 3.31-3.36 (m 2H), 3.55 (s, 3H), 4.80 (ddd, *J* = 6.5, 6.6, 6.7 Hz, 1H), 6.81 (d, *J* = 6.9 Hz, 1H), 7.19-7.22 (m, 1H), 7.27-7.30 (m, 1H), 7.37 (d, *J* = 8.1 Hz, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.88 (d, *J* = 1.1 Hz, 1H), 8.23 (d, *J* = 1.1 Hz, 1H), 9.23 (s, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 23.1 26.5 52.7 53.0 102.4 111.7 119.5 121.2 124.3, 124.4 127.4 128.6 133.6 134.6 170.5 172.2. IR (neat, cm<sup>-1</sup>): 3211, 3136, 3080, 1742, 1655, 1568, 1507, 1462, 1429, 1367, 1343, 1278, 1235, 1215, 1194, 1165, 1125, 1041, 1012, 791, 762, 716, 649, 546. HRMS (ESI): calcd for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>NaO<sub>3</sub> [M+Na]<sup>+</sup> 350.1229, found 350.1228.

### *N*-Acetyl-2-(pyrazol-1-yl)-L-tryptophan methyl ester (**8**)

To a mixture of Ac-Trp-OMe (**1**) (52 mg, 0.20 mmol), I<sub>2</sub> (12 mg, 0.047 mmol) and pyrazole (35 mg, 0.51 mmol) in a test tube were added MeOH (400 μL) and H<sub>2</sub>O (400 μL). The mixture was stirred for 5 min at room temperature. Then, 70% aqueous TBHP solution (56 μL, 0.40 mmol) was added to the mixture and the mixture was stirred for 48 h at 40 °C in ChemiStation<sup>TM</sup> (EYELA). The reaction was quenched by addition of saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (2 mL) and diluted with H<sub>2</sub>O (5 mL). The precipitates were collected by filtration and washed thoroughly with H<sub>2</sub>O to afford **8** (43 mg, 65% yield) as colorless solids. <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>): δ 1.76 (s, 3H), 3.15 (dd, *J* = 7.8, 14.3 Hz, 1H), 3.27 (dd, *J* = 6.9, 14.3 Hz, 1H), 3.44 (s, 3H), 4.45 (ddd, *J* = 7.1, 7.1, 7.4 Hz, 1H), 6.62 (dd, *J* = 2.0, 2.2 Hz, 1H), 7.06-7.09 (m, 1H), 7.14-7.17 (m, 1H), 7.36 (d, *J* = 8.0 Hz, 1H), 7.52 (d, *J* = 7.9 Hz, 1H), 7.87 (d, *J* = 1.6 Hz, 1H), 8.23 (d, *J* = 2.4 Hz, 1H), 8.49 (d, *J* = 6.9 Hz, 1H), 11.74 (s, 1H). <sup>13</sup>C NMR (151 MHz, DMSO-*d*<sub>6</sub>): δ 22.2, 25.6, 51.7, 53.0, 99.4, 107.3, 111.4, 118.4, 119.6, 122.0, 127.4, 130.6, 132.4, 133.0, 141.1, 169.2, 172.2. IR (neat, cm<sup>-1</sup>): 3220, 3052, 1733, 1651, 1574, 1525, 1467, 1439, 1416, 1366, 1335, 1282, 1225, 1211, 1172, 1129, 1055, 1011, 978, 953, 926, 875, 747, 732, 639, 603. HRMS (ESI): calcd for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>NaO<sub>3</sub> [M+Na]<sup>+</sup> 349.1276, found 349.1277.

## 7. Preparation of azole derivatives



#### **Methyl 1*H*-benzo[d][1,2,3]triazole-5-carboxylate (S4)**

To a suspension of carboxylic acid **S3** (816 mg, 5.00 mmol) in MeOH (40 mL) was added thionyl chloride (430  $\mu$ L, 5.9 mmol) dropwise in an ice bath. The mixture was stirred for 5 min. The temperature of the mixture was raised to reflux and maintained overnight under reflux. The reaction mixture was cooled to room temperature and concentrated in *vacuo*. The residue was diluted with a mixture of EtOH and EtOAc (10 mL and 60 mL) and washed with brine (40 mL). The remained organic materials in the aqueous layer were extracted with a mixture of EtOH and EtOAc (10 mL and 40 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo* to afford **S4** (813 mg, 92% yield) as brown solids. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  4.00 (s, 3H), 7.87 (br s, 1H), 8.19, (d, *J* = 8.7 Hz), 8.73 (s, 1H). These values were in good agreement with those reported in the literature.<sup>7</sup>

#### **5-Hydroxymethyl-1*H*-benzo[d][1,2,3]triazole (S5)**

To a suspension of LiAlH<sub>4</sub> (228 mg, 6.01 mmol) in anhydrous THF (20 mL) under argon atmosphere was added ester **S4** (708 mg, 4.00 mmol) in five portions over 1 h. The mixture was stirred overnight at room temperature. The mixture was quenched with EtOAc (200  $\mu$ L) and stirred for 1 h. The resulting mixture was poured into ice water (50 mL), acidified with 2 M aqueous HCl solution to pH  $\sim$ 3, and saturated with NaCl. The organic materials were extracted with EtOAc (50 mL) and THF (30 mL $\times$ 2). The combined organic layers were concentrated in *vacuo*. The resulting residue was purified with Isolera One flash purification system (CHCl<sub>3</sub>/MeOH, 19:1 to 10:1) to afford **S5** (411 mg, 69% yield) as orange solids. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  4.66 (s, 2H), 5.36 (s, 1H), 7.37 (s, 1H), 7.77 (br s, 1H), 7.86 (br s, 1H), 15.59, (s, 1H). These values were in good agreement with those reported in the literature.<sup>7</sup>

#### **5-(Azidomethyl)-1*H*-benzo[d][1,2,3]triazole (25)**


To a suspension of alcohol **S5** (296 mg, 2.0 mmol) in toluene (3.0 mL) was added thionyl chloride (2.0 mL) dropwise in an ice bath. The mixture was stirred for 5 min at the same temperature. The temperature of the mixture was raised to room temperature and the mixture was stirred for 3 h. The resulting precipitates were collected by filtration, washed with *n*-hexane (40 mL), and dried in *vacuo*. The resulting solids (372 mg) were directly used for the next step.

To a solution of the above solids in DMF (4 mL) was added NaN<sub>3</sub> (391 mg, 6.01 mmol). The mixture was stirred for 3 days at room temperature. The reaction mixture was diluted with H<sub>2</sub>O (10 mL) and the organic materials were extracted with EtOAc (30 mL, 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with Isolera One flash purification

system (hexane/ EtOAc, 40–50%) to afford **25** (313 mg, 90% yield from **S5**) as colorless solids. <sup>1</sup>H NMR (600 MHz, 5% TFA-*d* in CD<sub>3</sub>OD): δ 4.56 (s, 2H), 7.48 (dd, *J* = 1.3, 8.6 Hz, 1H), 7.87 (s, 1H), 7.90 (d, *J* = 8.6 Hz, 1H). <sup>13</sup>C NMR (151 MHz, 5% TFA-*d* in CD<sub>3</sub>OD): δ 55.4, 115.0, 116.2, 127.9, 136.0, 139.8, 140.1. IR (neat, cm<sup>-1</sup>): 2980, 2773, 2084, 1523, 1473, 1409, 1381, 1347, 1304, 1267, 1236, 1209, 1194, 1150, 1018, 998, 961, 892, 861, 827, 808, 772, 760, 706. HRMS (ESI): calcd for C<sub>7</sub>H<sub>5</sub>N<sub>6</sub> [M-H]<sup>-</sup> 173.0576, found 173.0571.

### 5-Hydroxymethyl-1*H*-1,2,3-triazole (**26**)

To a solution of CuI (39 mg, 0.20 mmol) in anhydrous DMF (4 mL) and MeOH (1 mL) under argon atmosphere were added propargyl alcohol (120 μL, 2.1 mmol) and TMSN<sub>3</sub> (390 μL, 3.0 mmol). The mixture was stirred at 80 °C for 21 h. Then, the reaction mixture was cooled to room temperature and concentrated in *vacuo*. The residue was suspended with EtOAc (30 mL) and the precipitates were removed by filtration through celite pad. The filtrate was concentrated in *vacuo* and the residue was purified by flush silica gel column chromatography (EtOAc) to afford **26** (151 mg, 74% yield) as colorless amorphous solids. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.90 (s, 1H), 4.86 (s, 2H), 7.72 (s, 1H). These values were in good agreement with those reported in the literature.<sup>8</sup>



### 1-(Azidomethyl)-4-methoxybenzene (**S8**)

To a solution of 4-methoxybenzyl chloride (**S7**) (827 mg, 5.27 mmol) in DMF (10 mL) was added sodium azide (406 mg, 6.25 mmol). The mixture was stirred at room temperature for 24 h. The mixture was diluted with Et<sub>2</sub>O (40 mL), washed with H<sub>2</sub>O (40 mL×2) and brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo* to afford **S8** (831 mg, 97% yield) as a colorless oil. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 3.82 (s, 3H), 6.90-6.92 (m, 2H), 7.24-7.26 (m, 2H). These values were in good agreement with those reported in the literature.<sup>9</sup>

#### Benzyl prop-2-yn-1-ylcarbamate (S10)

To a solution of amine **S9** (320  $\mu$ L, 5.0 mmol) and NaHCO<sub>3</sub> (839 mg, 9.99 mmol) in THF was added benzyl chloroformate (850  $\mu$ L, 6.0 mmol). The mixture was stirred at room temperature for 20 h. The reaction mixture was diluted with H<sub>2</sub>O (10 mL) and the organic materials were extracted with Et<sub>2</sub>O (30 mL $\times$ 3). The combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with Isolera One flash purification system (hexane/EtOAc, 10–20%) to afford **S10** (787 mg, 83% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  2.24 (t,  $J$  = 2.5 Hz, 1H), 4.00 (br d,  $J$  = 3.1 Hz, 2H), 4.92 (br s, 1H), 5.13 (s, 2H), 7.31–7.38 (m, 5H). These values were in good agreement with those reported in the literature.<sup>10</sup>

#### 1-(4-Methoxybenzyl)-4-(((benzyloxy)carbonyl)amino)methyl)-1H-1,2,3-triazol (S11)

To a solution of azide **S8** (655 mg, 10.1 mmol) and carbamate **S10** (755 mg, 3.99 mmol) in *t*-BuOH (10 mL) and H<sub>2</sub>O (10 mL) were added CuSO<sub>4</sub>·5H<sub>2</sub>O (51 mg, 0.21 mmol) and sodium ascorbate (79 mg, 0.40 mmol). The reaction mixture was stirred at room temperature for 13 h. The reaction mixture was diluted with EtOAc (100 mL) and filtered through celite pad. The organic layer was separated, washed with 100 mM aqueous EDTA·4Na solution (40 mL) and brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo* to afford **S11** (1.34 g, 95%) as colorless solids. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  3.94 (s, 3H), 4.41 (d,  $J$  = 6.0 Hz, 2H), 5.07 (s, 2H), 5.40 (s, 2H), 5.46 (s, 1H), 6.88 (d,  $J$  = 8.5 Hz, 2H), 7.20 (d,  $J$  = 8.5 Hz, 2H), 7.29–7.33 (m, 5H), 7.40 (s, 1H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  36.6, 53.8, 55.4, 66.9, 114.6, 121.7, 126.6, 128.1, 128.2, 128.6, 129.8, 136.5, 145.4, 156.4, 160.0. IR (neat, cm<sup>-1</sup>): 3382, 3323, 3107, 3062, 3007, 2952, 2837, 1687, 1612, 1587, 1512, 1456, 1426, 1377, 1325, 1303, 1240, 1174, 1144, 1127, 1106, 1056, 1033, 975, 920, 843, 826, 742, 709. HRMS (ESI): calcd for C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>NaO<sub>3</sub> [M+Na]<sup>+</sup> 375.1433, found 375.1430.

#### 4-Nitrophenyl prop-2-yn-1-yl carbonate (S13)

To a solution of 4-nitrophenyl chloroformate (1.01 g, 5.01 mmol) in anhydrous THF (20 mL) under argon atmosphere were added trimethylamine (830  $\mu$ L, 6.0 mmol) and propargyl alcohol (295  $\mu$ L, 5.0 mmol) in an ice bath. The mixture was stirred for 1 h. The mixture was diluted with EtOAc (20 mL), washed with sat. NH<sub>4</sub>Cl aq. soln. (20 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with Isolera One flash purification system (hexane/EtOAc, 10:1 to 1:1) to afford **S13** (445 mg, 40% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 2.62 (t,  $J$  = 2.5 Hz, 1H), 4.88 (d,  $J$  = 2.5 Hz, 2H), 7.39–7.42 (m, 2H), 8.28–8.30 (m, 2H). These values were in good agreement with

those reported in the literature.<sup>11</sup>


**1-(4-Methoxybenzyl)-4-({[(prop-2-yn-1-yloxy)carbonyl]amino}methyl)-1H-1,2,3-triazol (S14)**

To a solution of carbamate **S11** (353 mg, 1.00 mmol) in THF (10 mL) was added 10% Pd/C (47 mg). The mixture stirred overnight at room temperature under H<sub>2</sub> atmosphere. The reaction mixture was filtered through a celite pad and concentrated in *vacuo*. The resulting solid (224 mg) was directly used for the next step.

To a solution of the residue and trimethylamine (210  $\mu$ L, 1.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added carbonate **S13** (206 mg, 0.931 mmol). The mixture was stirred at room temperature for 20 h. The reaction mixture was diluted with saturated aqueous Na<sub>2</sub>CO<sub>3</sub> solution (20 mL) and the organic materials were extracted with CH<sub>2</sub>Cl<sub>2</sub> (40 mL $\times$ 3). The combined organic layers were washed with brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with flush silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 19:1) to afford **S14** (241 mg, 80% yield from **S11**) as colorless solids. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  3.47 (t, *J* = 2.4 Hz), 3.73 (s, 3H), 4.21 (d, *J* = 5.9 Hz, 2H), 4.61 (d, *J* = 2.4 Hz, 2H), 5.47 (s, 2H) 6.92 (d, *J* = 8.7 Hz, 2H), 7.29 (d, *J* = 8.7 Hz, 2H), 7.83 (t, *J* = 5.7 Hz, 1H), 7.90 (s, 1H). These values were in good agreement with those reported in the literature.<sup>12</sup>

**4-({[(Prop-2-yn-1-yloxy)carbonyl]amino}methyl)-1H-1,2,3-triazol (27)**

To carbamate **S14** (132 mg, 0.440 mmol) was added TFA (1.6 mL). The mixture was stirred for 2 days under reflux. The reaction mixture was cooled to room temperature and concentrated in *vacuo*. The residue was dissolved in EtOAc (30 mL) and the desired product was extracted with 2 M aqueous NaOH solution (10 mL and 5 mL). The combined aqueous layers were acidified to pH ~3 with 2 M aqueous HCl solution and the organic materials were extracted with EtOAc (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified with silica gel column chromatography (hexane/ EtOAc, 1:2) to afford **27** (50 mg, 63% yield) as colorless solids. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  3.48 (t, *J* = 2.2 Hz, 1H, major and minor tautomers), 4.26 (s, 2H, major and minor), 4.63 (d, *J* = 2.2 Hz, 2H major and minor), 7.50 (s, 1H, minor), 7.59 (s, 1H, major), 7.86 (s, 1H, major and minor), 14.69 (s, 1H, major), 15.08 (s, 1H, minor). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>, major tautomer):  $\delta$  35.8, 51.7, 77.2, 79.3, 132.1, 145.2, 155.4. IR (neat, cm<sup>-1</sup>): 3296, 3163, 3112, 3078, 3006, 2360, 1692, 1555, 1443, 1396, 1355, 1308, 1276, 1220, 1147, 1126, 1050, 1025, 1004, 992, 961, 885, 849, 781, 764, 664, 636. HRMS (ESI): calcd for C<sub>7</sub>H<sub>8</sub>N<sub>4</sub>NaO<sub>2</sub> [M+Na]<sup>+</sup> 203.0545, found 203.0542.



### 3-(1-Benzyl-1H-1,2,3-triazol-4-yl)propan-1-ol (S17)

To a solution of benzyl bromide (594  $\mu\text{L}$ , 5.00 mmol) in acetone (80 mL) and  $\text{H}_2\text{O}$  (20 mL) was added sodium azide (487 mg, 7.50 mmol). The mixture was stirred at room temperature for 14 h. The reaction mixture was diluted with  $\text{H}_2\text{O}$  (40 mL) and the organic materials were extracted by  $\text{CH}_2\text{Cl}_2$  (50, 20, 20 mL). The combined organic layers were dried over  $\text{Na}_2\text{SO}_4$ , filtered through cotton plug, and concentrated in *vacuo* to afford **S15** (658 mg) as a colorless oil.

To a solution of **S15** in *t*-BuOH (15 mL) and  $\text{H}_2\text{O}$  (5 mL) were added 4-pentyn-1-ol (456  $\mu\text{L}$ , 4.93 mmol),  $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$  (101 mg, 0.503 mmol), and sodium ascorbate (197 mg, 0.996 mmol). The reaction mixture was stirred at room temperature for 20 h under Ar atmosphere and concentrated in *vacuo*. The residue was suspended with  $\text{H}_2\text{O}$  (10 mL) and the organic materials were extracted with  $\text{CHCl}_3$  (20 mL x 3). The combined organic layers were dried over  $\text{Na}_2\text{SO}_4$ , filtered through cotton plug, and concentrated in *vacuo*. The resulting residue was purified using Isolera One system ( $\text{CHCl}_3/\text{MeOH}$ , 2—18%) to afford **S16** (1032 mg, 95% yield from **S15**) as colorless solids.  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3/\text{TMS}$ ):  $\delta$  1.92 (tt,  $J = 6.0, 7.3$  Hz, 2H), 2.81 (t,  $J = 7.3$  Hz, 2H), 3.70 (t,  $J = 6.0$  Hz, 2H), 5.49 (s, 2H), 7.22 (s, 1H), 7.25–7.27 (m, 2H), 7.35–7.38 (m, 3H).  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  22.1, 31.9, 54.1, 61.8, 120.9, 128.0, 128.7, 129.1, 134.8, 148.0. HRMS (ESI): calcd for  $\text{C}_{12}\text{H}_{15}\text{N}_3\text{NaO}$   $[\text{M}+\text{Na}]^+$  240.1113, found 240.1121.


### 3-(1-Benzyl-1H-1,2,3-triazol-4-yl)propanal (S17)

To a solution of oxalyl chloride (685  $\mu\text{L}$ , 7.99 mmol) in  $\text{CH}_2\text{Cl}_2$  (6 mL) in three-necked flask fitted with an Ar balloon and a thermometer at  $-70^\circ\text{C}$  in a dry ice–acetone bath was added dropwise a solution of DMSO (850  $\mu\text{L}$ , 12.0 mmol) in  $\text{CH}_2\text{Cl}_2$  (6 mL). The mixture was stirred for 5 min at the same temperature. To the mixture was added dropwise a solution of **S16** (874 mg, 4.02 mmol) in  $\text{CH}_2\text{Cl}_2$  (6 mL) over 10 min. The resulting mixture was stirred for 1 h at the same temperature. To the mixture was added  $\text{Et}_3\text{N}$  (3.35 mL, 24.0 mmol). A dry ice–acetone bath was

removed, and the mixture was stirred for 30 min. The mixture was quenched with sat.  $\text{NH}_4\text{Cl}$  aq. solution (40 mL). The organic materials were extracted with  $\text{CHCl}_3$  (30 mL x 2). The combined organic layers were dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated *in vacuo*. The resulting residue was purified by using Isolera One system ( $\text{CHCl}_3/\text{MeOH}$ , 2—18%) to afford **S17** (793 mg, 92% yield) as orange oil.  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3/\text{TMS}$ ):  $\delta$  2.91 (dt,  $J = 0.9, 7.0$  Hz, 2H), 3.01 (t,  $J = 7.0$  Hz, 2H), 5.48 (s, 2H), 7.25–7.26 (m, 3H), 7.36–7.37 (m, 3H), 9.82 (t,  $J = 0.9$  Hz, 1H).  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  201.2, 146.6, 134.8, 129.1, 128.7, 128.0, 121.2, 54.1, 43.0, 18.2. HRMS (ESI): calcd for  $\text{C}_{12}\text{H}_{13}\text{N}_3\text{NaO}$   $[\text{M}+\text{Na}]^+$  238.0956, found 238.0958.

### 6-Methoxy-5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazole (**28**)


To a solution of **S17** (97 mg, 0.45 mmol) in MeOH (5 mL) were added 10% Pd/C (29 mg) and 1,1,2-trichloroethane (44.5  $\mu\text{L}$ , 0.497 mmol). The suspension was stirred for 48 h under 1 atom of hydrogen at rt. The mixture was filtered through a celite pad and the filtrate was concentrated *in vacuo* to afford colorless oil (69 mg). Low-resolution MS data indicated that the product was a mixture of **28** and **28'** (Fig. S29). The resulting oil was dissolved in DMSO and was directly used for stapling of **13** without further purification.



**Fig. S29** Low-resolution MS data of **28**.


# <sup>1</sup>H and <sup>13</sup>C NMR spectra of synthesized compounds

<sup>1</sup>H NMR of 1 (500 MHz, CDCl<sub>3</sub>)








$^{13}\text{C}$  NMR of **1** (126 MHz,  $\text{CDCl}_3$ )





<sup>1</sup>H NMR of 4 (500 MHz, CDCl<sub>3</sub>)




$^{13}\text{C}$  NMR of 4 (126 MHz,  $\text{CDCl}_3$ )





<sup>1</sup>H NMR of S1 (500 MHz, DMSO-d<sub>6</sub>)




$^{13}\text{C}$  NMR of S1 (126 MHz, DMSO- $d_6$ )



<sup>1</sup>H NMR of S2 (500 MHz, DMSO-d<sub>6</sub>)




$^{13}\text{C}$  NMR of S2 (126 MHz, DMSO- $d_6$ )










$^{13}\text{C}$  NMR of **6** (126 MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR of 7 (500 MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR of 7 (126 MHz,  $\text{CDCl}_3$ )





$^1\text{H}$  NMR of **8** (500 MHz,  $\text{CDCl}_3$ )




$^{13}\text{C}$  NMR of **8** (126 MHz,  $\text{CDCl}_3$ )





$^1\text{H}$  NMR of **25** (600 MHz, 5% TFA-d in  $\text{CD}_3\text{OD}$ )



$^{13}\text{C}$  NMR of **25** (151 MHz, 5% TFA-d in  $\text{CD}_3\text{OD}$ )




$^1\text{H}$  NMR of **S11** (600 MHz,  $\text{CDCl}_3$ )








$^{13}\text{C}$  NMR of S11 (151 MHz,  $\text{CDCl}_3$ )





$^1\text{H}$  NMR of **27** (500 MHz,  $\text{DMSO-d}_6$ )




$^{13}\text{C}$  NMR of **27** (126 MHz, DMSO- $d_6$ )




<sup>1</sup>H NMR of S16 (600 MHz, CDCl<sub>3</sub>/TMS)




$^{13}\text{C}$  NMR of **S16** (151 MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR of S17 (600 MHz,  $\text{CDCl}_3/\text{TMS}$ )



$^{13}\text{C}$  NMR of S17 (151 MHz,  $\text{CDCl}_3$ )




$^1\text{H}$  NMR of **23** (600 MHz, DMSO- $d_6$ )







$^{13}\text{C}$  NMR of **23** (151 MHz, DMSO- $d_6$ )




$^1\text{H}$  NMR of TP-13 (600 MHz, DMSO- $d_6$ )




<sup>13</sup>C NMR of TP-13 (151 MHz, DMSO-d<sub>6</sub>)



$^1\text{H}$  NMR of **29** (600 MHz, DMSO- $d_6$ )



$^{13}\text{C}$  NMR of **29** (151 MHz, DMSO- $d_6$ )



## References

- 1 D. Beukeaw, K. Udomsasporn and S. Yotphan, *J. Org. Chem.*, 2015, **80**, 3447–3454.
- 2 A. R. Katritzky, X. Lan, J. Z. Yang and O. V. Denisko, *Chem. Rev.*, 1998, **98**, 409–548.
- 3 N. M. Alexander, *J. Biol. Chem.*, 1974, **249**, 1946–1952.
- 4 C. N. Pace, F. Vajdos, L. Fee, G. Grimsley and T. Gray, *Protein Sci.*, 1995, **4**, 2411–2423.
- 5 S. Sato and H. Nakamura, *Angew. Chem., Int. Ed.*, 2013, **52**, 8681–8684.
- 6 T. J. Williams, A. J. Reay, A. C. Whitwood and I. J. S. Fairlamb, *Chem. Commun.*, 2014, **50**, 3052–3054.
- 7 M. Krasavin, D. Pershin, D. Larkin and D. Kravchenko, *Synth. Commun.*, 2005, **35**, 2587–2595.
- 8 H. D. Velázquez, Y. R. García, M. Vandichel, A. Madder and F. Verpoort, *Org. Biomol. Chem.*, 2014, **12**, 9350–9356.
- 9 S. Lal, H. S. Rzepa and S. Díez-González, *ACS Catal.*, 2014, **4**, 2274–2287.
- 10 L. C. Wilkins, P. Wieneke, P. D. Newman, B. M. Kariuki, F. Rominger, A. S. K. Hashmi, M. M. Hansmann and R. L. Melen, *Organometallics*, 2015, **34**, 5298–5309.
- 11 H. Egami, S. Kamisuki, K. Dodo, M. Asanuma, Y. Hamashima and M. Sodeoka, *Org. Biomol. Chem.*, 2011, **9**, 7667–7670.
- 12 G. Colombano, C. Albani, G. Ottonello, A. Ribeiro, R. Scarpelli, G. Tarozzo, J. Daglian, K.-M. Jung, D. Piomelli and T. Bandiera, *ChemMedChem*, 2015, **10**, 380–395.